Before use in the clinic, the efficacy and side effects of this promising triple-combination BRAFi + MEKi + anti-PD-1/ PD-L1 are currently being explored in BRAF mutated ATC, PDTC or MTC in the NCT03181100clinical trial (Table 5). The gene discussed is CD274; the disease is medullary thyroid gland carcinoma.